4basebio (4BB)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 725.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 1,350.00p
  • 52 Week Low: 703.85p
  • Currency: UK Pounds
  • Shares Issued: 15.54m
  • Volume: 13
  • Market Cap: £112.65m

4basebio makes progress with manufacturing development

By Josh White

Date: Tuesday 15 Feb 2022

LONDON (ShareCast) - (Sharecast News) - Specialist life sciences company 4basebio updated the market on its synthetic DNA business on Tuesday, having added Mark Cooper its as head of manufacturing in December, alongside further senior hires across its manufacturing, quality assurance and business development teams in recent months.
The AIM-traded firm said Cooper had joined from Abcam, and had assumed responsibility for the group's manufacturing facility.

Despite supply chain and Covid-19-related challenges during construction, the company said the development of phase one, comprising four synthesis rooms, was now complete.

Phase two, consisting of three further synthesis rooms, was expected to be completed in March, with the overall development to be completed within budget.

As it previously reported, the facility would be undergoing testing and validation during the second quarter of 2022.

4basebio said it then planned to manufacture and sell research and preclinical-grade DNA, while working towards securing 'Good Manufacturing Practice' (GMP) approvals.

4basebio also confirmed that the facility handover coincided with the company's first commercial order for research-grade DNA.

"The combination of the handover of the clean rooms, recruitment of the manufacturing and quality assurance teams and the first commercial sale of product all represent important milestones for 4basebio and its key strategic objective of commercialising its synthetic DNA technology," said chief executive and scientific officer Heikki Lanckriet.

"4basebio has made significant progress over the past year, with this update coming a little over a year since the spin out from its former parent company.

"The prospects both for the group's DNA technology as well as its non-viral delivery technology remain very exciting," Dr Lanckriet added.

At 1100 GMT, shares in 4basebio were flat at 600p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

4basebio Market Data

Currency UK Pounds
Share Price 725.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 1,350.00p
52 Week Low 703.85p
Volume 13
Shares Issued 15.54m
Market Cap £112.65m

4basebio Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
65.49% below the market average65.49% below the market average65.49% below the market average65.49% below the market average65.49% below the market average
12.20% above the sector average12.20% above the sector average12.20% above the sector average12.20% above the sector average12.20% above the sector average
Price Trend
34.27% below the market average34.27% below the market average34.27% below the market average34.27% below the market average34.27% below the market average
4.55% above the sector average4.55% above the sector average4.55% above the sector average4.55% above the sector average4.55% above the sector average
Income Not Available
Growth
59.11% above the market average59.11% above the market average59.11% above the market average59.11% above the market average59.11% above the market average
65.52% above the sector average65.52% above the sector average65.52% above the sector average65.52% above the sector average65.52% above the sector average

4basebio Dividends

No dividends found

Trades for 24-Oct-2025

Time Volume / Share Price
08:00 13 @ 705.00p

4basebio Key Personnel

CEO Heikki Lanckriet
CFO David John Roth

Top of Page